样式: 排序: IF: - GO 导出 标记为已读
-
Monotherapy or combination therapy in PsA: current aspects Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-09-19 Elpida Skouvaklidou, Paraskevi Avgerou, Konstantinos D. Vassilakis, George E. Fragoulis, Nikolaos Kougkas
Psoriatic arthritis (PsA) is an immune-mediated inflammatory disease with heterogeneity regarding its clinical features, mainly affecting the skin and the musculoskeletal system; additionally, extra-musculoskeletal manifestations and comorbidities are common, adding complexity to its treatment. In the last decades, a plethora of therapeutic options have been available, including conventional synthetic
-
Bone marrow edema in children: chronic nonbacterial osteomyelitis and its mimickers Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-09-19 Chiara Giraudo, Giulia Fichera, Anna Michielin, Francesco Zulian, Roberto Stramare, Winston J. Rennie
Bone marrow is a highly cellular tissue undergoing significant developmental and physiologic changes with age. Indeed, with maturation from pediatric to the adult age there is a progressive, centrifugal conversion from red to yellow bone marrow. Histological characteristics of bone marrow are reflected in MR image signal. MR is therefore extremely sensitive in detecting pathological changes which are
-
Knee osteoarthritis: disease burden, available treatments, and emerging options Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-09-17 Michael Langworthy, Vinod Dasa, Andrew I. Spitzer
Osteoarthritis (OA) is a prevalent condition that affects nearly 528 million people worldwide, including 23% of the global population aged ⩾40, and is characterized by progressive damage to articular cartilage, which often leads to substantial pain, stiffness, and reduced mobility for affected patients. Pain related to OA is a barrier to maintaining physical activity and a leading cause of disability
-
Cardiovascular comorbidities in psoriatic arthritis: state of the art Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-09-14 Mrinalini Dey, Elena Nikiphorou
Psoriatic arthritis (PsA) is a complex multi-system immune-mediated condition, characterised by a high comorbidity burden, one of the most prevalent of which is cardiovascular disease (CVD), affecting up to 80% of patients. This narrative review explores the current understanding of cardiovascular comorbidities in PsA, focusing on mechanistic pathways, risk assessment, and the impact of treatment choices
-
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-09-07 Desirée Ruiz-Vilchez, Lourdes Ladehesa-Pineda, María Ángeles Puche-Larrubia, María Carmen Ábalos-Aguilera, Pilar Font-Ugalde, Alejandro Escudero-Contreras, Eduardo Collantes-Estévez, Clementina López-Medina
Background:Few studies have been conducted to investigate the socioeconomic profiles of patients with ankylosing spondylitis (AS) and their associations with disease severity and disability.Objectives:The objectives of this study were to identify clusters of patients with AS according to their socioeconomic characteristics and to evaluate the associations between these clusters and the severity of
-
Meibomian gland dropout of upper eyelids as a novel biomarker for early diagnosis of primary Sjögren’s syndrome: a pilot study Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-09-02 Jing Wu, Yongying Liang, Fanjun Shi, Xianghong Tu, Jingfa Zhang, Qinghua Qiu
Background:Early diagnosis of primary Sjögren’s syndrome (pSS) remains difficult due to its insidious onset.Objectives:To identify whether meibomian gland dropout (MGD) is a sensitive and noninvasive predictor of pSS by studying its association with histopathology in labial salivary gland biopsy in patients with clinically suspected pSS.Design:Prospective, randomized, multicenter, comparative effectiveness
-
Switching related to inefficacy in biologics and targeted synthetic therapies for psoriatic arthritis: a comparative real-life study Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-08-31 Dalifer Freites-Nuñez, Leticia Leon, Esther Toledano, Gloria Candelas, Cristina Martinez, Maria Rodriguez-Laguna, Daniel Rubio, Benjamin Fernandez-Gutierrez, Lydia Abasolo
Background:Switching between therapies is a recommended strategy for psoriatic arthritis (PsA) patients who experience treatment failure; however, studies including real-life data are scarce.Objectives:To assess the incidence rate (IR) of switching between biologics and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) due to inefficacy in PsA, and to compare the risk of switching
-
Effects of acupuncture versus placebo on clinical status and potential specific effects in Fibromyalgia: an umbrella review of 11 meta-analyses. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-08-20 Felipe Araya-Quintanilla,Robinson Ramirez-Vélez,Guillermo Mendez-Rebolledo,Iván Cuyul-Vásquez,Alexis Arce-Álvarez,Yasmin Ezzatvar,Héctor Gutiérrez-Espinoza
Background The use of acupuncture is related to patients' expectations, and the therapeutic interaction effect remains a topic of debate in the literature. Accordingly, it is still unclear whether acupuncture can generate positive clinical effects in patients with fibromyalgia (FM). Objective To determine the effectiveness of acupuncture versus placebo for clinical outcomes and determine the overall
-
Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-08-19 Jacob Corum Williams, Ryan Malcolm Hum, Kira Rogers, Cristina Maglio, Uazman Alam, Sizheng Steven Zhao
Psoriatic arthritis (PsA) is an inflammatory joint and entheseal disease associated with significant personal and public health burden. PsA has a prevalence of up to 1%, affecting ~20% of people suffering with psoriasis. PsA is frequently accompanied by metabolic syndrome (MetS), and both conditions are characterised by a chronic pro-inflammatory state, with several key cytokines in PsA (interleukin
-
The signature of the gut microbiota associated with psoriatic arthritis revealed by metagenomics Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-08-10 Wei Liu, Chunyan Li, Wenhui Xie, Yong Fan, Xiaohui Zhang, Yu Wang, Lei Li, Zhuoli Zhang
Background:Gut microbiota is involved in the development of psoriatic arthritis (PsA), but until now, there has been a lack of understanding of the PsA host–bacteria interaction.Objectives:To reveal the labels of gut microbiota in PsA patients and the species and functions related to disease activity.Design:Observational research (cross-sectional) with an exploratory nature.Methods:Metagenomics sequencing
-
Early psoriatic arthritis: when is the right time to start advanced therapy? Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-07-28 Or Hen, Stephanie R. Harrison, Gabriele De Marco, Helena Marzo-Ortega
Despite significant advances in the treatment of psoriatic arthritis (PsA) in the last two decades, remission remains elusive and there is no cure. Evidence from rheumatoid arthritis (RA) confirming enhanced response and outcome from earlier treatment intervention suggests the plausibility of the window of opportunity in the pathogenesis of RA. Yet, data are lacking in PsA. Although treatment response
-
Minodronate for severe multiple vertebral fractures due to pregnancy- and lactation-associated osteoporosis: a case report and literature review Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-07-27 Kuniaki Ota, Yuta Asanuma, Hideyuki Hirasawa, Hiroaki Ohta, Toshifumi Takahashi
Pregnancy- and lactation-associated osteoporosis (PLO) is a rare type of premenopausal osteoporosis, typically occurring during the third trimester of pregnancy and the early postpartum lactation period. This report presents a case involving severe multiple vertebral fractures due to PLO with low bone mineral density (BMD) and heightened bone turnover. A 39-year-old primiparous Japanese woman reported
-
Efficacy and NSAID-sparing effect of secukinumab 150 mg in ankylosing spondylitis: results from phase IV ASTRUM study. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-06-05 Uta Kiltz,Xenofon Baraliakos,Jan Brandt-Jürgens,Ulf Wagner,Sebastian Lieb,Christian Sieder,Christian Mann,Jürgen Braun
Background Radiographic axial spondyloarthritis (r-axSpA), formerly known as ankylosing spondylitis (AS), is a chronic, inflammatory rheumatic disease associated with symptoms such as inflammatory back pain, morning stiffness, and arthritis. First-line recommendations for patients with AS include treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) for reducing pain and stiffness. Objectives
-
Diagnosing vasculitis with ultrasound: findings and pitfalls. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-06-05 Wolfgang A Schmidt,Valentin S Schäfer
Rheumatologists are increasingly utilizing ultrasound for suspected giant cell arteritis (GCA) or Takayasu arteritis (TAK). This enables direct confirmation of a suspected diagnosis within the examination room without further referrals. Rheumatologists can ask additional questions and explain findings to their patients while performing ultrasound, preferably in fast-track clinics to prevent vision
-
The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trial Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-05-31 Marion Watson, William Tillett, Deepak Jadon, M. Sofia Massa, Anne Francis, Nicola Gullick, Ines Rombach, Yvonne Sinomati, Laura Tucker, Laura C. Coates
Objectives:The aim of the Severe Psoriatic arthritis – Early intervEntion to control Disease trial is to compare outcomes in psoriatic arthritis (PsA) patients with poor prognostic factors treated with standard step-up conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), combination csDMARDs or a course of early biologics.Design:This multicentre UK trial was embedded within the
-
Intramuscular methylprednisolone administration in hand osteoarthritis patients: a feasibility study to inform a randomized controlled trial Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-05-27 Merel Hartog, Kyra A. L. van Keeken, Cornelia H. M. van den Ende, Calin D. Popa
Background:Inflammation is thought to play an important role in hand osteoarthritis (HOA), which is associated with pain and increased limitation of hand function.Objectives:To explore the acceptability of therapy with intramuscular methylprednisolone in HOA among health-care providers (HCPs) and HOA patients. Additionally, the response to a single methylprednisolone injection was investigated.Design:We
-
The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-05-23 Antimo Moretti, Francesco Snichelotto, Sara Liguori, Marco Paoletta, Giuseppe Toro, Francesca Gimigliano, Giovanni Iolascon
Musculoskeletal disorders are characterized by several impairments, including pain, affecting muscles, bones, joints and adjacent connective tissue, resulting in temporary or permanent functional limitations and disability. Musculoskeletal pain is particularly prevalent worldwide and greatly impacts the quality of life, social participation and economic burden. To date, several issues persist about
-
Effectiveness and safety of immunoadsorption as a rescue treatment of inflammatory myopathies: report of three cases and literature review Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-05-17 Jasper F. Nies, Claudia Hendrix, Malte P. Bartram, Ryan Spear, Henning Hagmann, Thomas Benzing, Torsten Kubacki
Idiopathic inflammatory myopathy (IIM) summarizes rare, systemic autoimmune conditions primarily characterized by inflammatory damage to the skeletal muscle. Although primary damage occurs to the muscle, these IIM-related conditions involve other organs, including the skin, lungs, upper gastrointestinal tract, joints, and heart. While many patients have an adequate response to immunosuppressive treatment
-
Automated osteoporosis classification and T-score prediction using hip radiographs via deep learning algorithm Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-04-25 Yu-Pin Chen, Wing P. Chan, Han-Wei Zhang, Zhi-Ren Tsai, Hsiao-Ching Peng, Shu-Wei Huang, Yeu-Chai Jang, Yi-Jie Kuo
Background:Despite being the gold standard for diagnosing osteoporosis, dual-energy X-ray absorptiometry (DXA) is an underutilized screening tool for osteoporosis.Objectives:This study proposed and validated a controllable feature layer of a convolutional neural network (CNN) model with a preprocessing image algorithm to classify osteoporosis and predict T-score on the proximal hip region via simple
-
The sequential antifracturative treatment: a meta-analysis of randomized clinical trials Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-04-23 Angelo Fassio, Davide Gatti, Annalisa Biffi, Raffaella Ronco, Gloria Porcu, Giovanni Adami, Rosaria Alvaro, Riccardo Bogini, Achille P. Caputi, Luisella Cianferotti, Bruno Frediani, Stefano Gonnelli, Giovanni Iolascon, Andrea Lenzi, Salvatore Leone, Raffaella Michieli, Silvia Migliaccio, Tiziana Nicoletti, Marco Paoletta, Annalisa Pennini, Eleonora Piccirilli, Maurizio Rossini, Maria Luisa Brandi,
Background:Subjects with a fragility fracture have an increased risk of a new fracture and should receive effective strategies to prevent new events. The medium-term to long-term strategy should be scheduled by considering the mechanisms of action in therapy and the estimated fracture risk.Objective:A systematic review was conducted to evaluate the sequential strategy in patients with or at risk of
-
Costotransverse joint ankylosis and their association with syndesmophyte progression in patients with radiographic axial spondyloarthritis Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-04-05 Hong Ki Min, Se Hee Kim, Sang-Heon Lee, Hae-Rim Kim, Sang-Hoon Lee
Background:Abnormal new bone formation can occur not only in the vertebral body but also can occur in facet, costovertebral, and costotransverse joints in radiographic axial spondyloarthritis (r-axSpA) patients. Little is known about the association between syndesmophyte progression and paravertebral joint ankylosis in r-axSpA.Objectives:Costotransverse joint ankylosis in r-axSpA patients was measured
-
The association between gout flares and monosodium urate burden assessed using musculoskeletal ultrasound in patients with gout Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-03-30 Shaoling Yang, Xiaojing Lin, Yining Gao, Nan Liang, Yali Han, Hang Sun, Shen Qu, Haibing Chen
Background:Ultrasound (US) has a high sensitivity in detecting monosodium urate (MSU) deposition in gout patients. However, the value of US in predicting gout flares has been reported only in a few monocentric studies.Objective:To investigate the association between gout flares in the previous year and US-detected MSU burden using two different US scores.Design:A retrospective study.Methods:Patients
-
The sacroiliac joint across ages – what is normal? Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-03-29 Anne Grethe Jurik, Nele Herregods
The anatomy of the sacroiliac joint (SIJ) is complex with wide variations inter-individually as well as intra-individually (right versus left) and a frequent occurrence of anatomical variants. Besides, the joints are subject to strain, which may elicit non-inflammatory subchondral changes such as bone marrow edema (BME), sclerosis, and fat deposition simulating inflammatory SIJ changes. Furthermore
-
Dispositional traits help explain individual differences in relationships between a radiographic knee osteoarthritis measure, pain, and physical function Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-03-21 Angela M. Mickle, Roland Staud, Cynthia S. Garvan, Daniel A. Kusko, Nicola Sambuco, Brittany R. Addison, Kevin R. Vincent, David T. Redden, Burel R. Goodin, Roger B. Fillingim, Kimberly T. Sibille
Background:The concordance between radiograph-derived Kellgren–Lawrence (KL) scores for knee osteoarthritis (KOA) and experimental and clinical pain and KOA-related physical function is conflicting.Objectives:We investigate whether the inclusion of dispositional traits reduces variability between KOA radiographic findings, experimental pain, clinical pain, and function in individuals with knee pain
-
To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-02-28 Delphine Bertrand, Anke Deprez, Michaël Doumen, Diederik De Cock, Sofia Pazmino, Anja Marchal, Marc Thelissen, Johan Joly, Elias De Meyst, Barbara Neerinckx, René Westhovens, Patrick Verschueren
Background:Several retreatment strategies exist for rituximab in rheumatoid arthritis (RA). In some countries, reimbursement criteria require a loss of disease control for rituximab retreatment. Understanding the patients’ and rheumatologists’ perceptions regarding this retreatment strategy would be informative in identifying the optimal treatment administration schedule.Objectives:This study aimed
-
Impact of daily physical therapy over 2 weeks on spinal mobility including objective electronic measurements and function in patients with axial spondyloarthritis Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-02-23 David Kiefer, Lucia Schneider, Juergen Braun, Uta Kiltz, Niklas Kolle, Ioana Andreica, Styliani Tsiami, Bjoern Buehring, Philipp Sewerin, Susanne Herbold, Xenofon Baraliakos
Background:Patients with axial spondyloarthritis (axSpA) are often compromised by impaired function and mobility. The standardized 2-week inpatient program ‘multimodal rheumatologic complex treatment’ (MRCT) was designed for patients with axSpA. The Epionics SPINE (ES) is an objective tool validated to assess mobility.Objective:To investigate the impact of MRCT on physical function and mobility including
-
Effects of adipose-derived mesenchymal stem cell conditioned medium on human tenocytes exposed to high glucose Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2024-01-08 Maria Consiglia Trotta, Annalisa Itro, Caterina Claudia Lepre, Marina Russo, Francesca Guida, Antimo Moretti, Adriano Braile, Umberto Tarantino, Michele D’Amico, Giuseppe Toro
Introduction:Diabetic tendinopathy is a common invalidating and challenging disease that may be treated using stem cells. However, the effects of adipose-derived mesenchymal stem cell conditioned medium (ASC-CM) in diabetic tendinopathy have never been explored.Objectives:The present study evaluated the effects of ASC-CM on morphology, cell viability, structure, and scratch wound closure of human tenocytes
-
Risk factors for interstitial lung disease in rheumatoid arthritis: a cohort study from the KOBIO registry. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-12-30 Hong Ki Min,Se Hee Kim,Sang-Heon Lee,Hae-Rim Kim
Background Interstitial lung disease (ILD) is a critical extra-articular manifestation of rheumatoid arthritis (RA). However, little is known about the risk factors of RA-ILD. Objectives Here, we examined the effect of demographic, clinical, therapeutic, and environmental factors on the incidence of ILD in RA patients using the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry
-
Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-12-24 Diego Benavent,Santiago Muñoz-Fernández,Isabel De la Morena,Antonio Fernández-Nebro,Judith Marín-Corral,Eva Castillo Rosa,Miren Taberna,Cristina Sanabra,Carlos Sastre,
Background Spondyloarthritis (SpA) is a group of related but phenotypically distinct inflammatory disorders that include axial SpA (axSpA) and psoriatic arthritis (PsA). Information on the characteristics and management of these patients in the real world remains scarce. Objectives To explore the characteristics and management [disease activity assessment and treatment with secukinumab (SEC) or other
-
The role of the fracture liaison service in the prevention of atypical femoral fractures. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-11-28 Giuseppe Toro,Adriano Braile,Sara Liguori,Antimo Moretti,Giovanni Landi,Antonio Benedetto Cecere,Gianluca Conza,Annalisa De Cicco,Umberto Tarantino,Giovanni Iolascon
Osteoporosis and fragility fractures (FFs) are considered critical health problems by the World Health Organization (WHO) because of high morbidity, mortality, and healthcare costs. The occurrence of a FF raises the risk of a subsequent fracture (refracture). The hip is the most common site of fragility refracture, and its onset is associated with a further increase in patient's morbidity, mortality
-
Effects of TNF-α inhibition versus secukinumab on active ultrasound-confirmed enthesitis in psoriatic arthritis. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-11-16 Ashley Elliott,Gary Wright,Adrian Pendleton,Madeleine Rooney
Introduction Enthesitis is a hallmark of psoriatic disease, but its clinical assessment is problematic in terms of diagnostic sensitivity and overlap with other comorbid conditions. Ultrasound is a useful tool that can give a more detailed assessment of enthesitis. Research demonstrates that those with persistent ultrasound entheseal disease are at risk of progressive articular damage. With limited
-
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-11-06 George A Karpouzas,Zoltán Szekanecz,Eva Baecklund,Ted R Mikuls,Deepak L Bhatt,Cunshan Wang,Gosford A Sawyerr,Yan Chen,Sujatha Menon,Carol A Connell,Steven R Ytterberg,Mahta Mortezavi
Background In patients with rheumatoid arthritis (RA), persistent inflammation and increasing disease activity are associated with increased risk of adverse events (AEs). Objectives To assess relationships between RA disease activity and AEs of interest in patients treated with tofacitinib or tumor necrosis factor inhibitors (TNFi). Design This was a post hoc analysis of a long-term, postauthorization
-
The predictability of ASDAS on drug survival in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-10-09 Jinhyun Kim,Min Jung Kim,Geun Young Oh,Sun Kyung Lee,Taeeun Kim,Kichul Shin
Background The Ankylosing Spondylitis (AS) Disease Activity Score (ASDAS) is largely used for assessing disease activity in patients with AS. Objectives We aimed to investigate the predictability of ASDAS on drug survival in patients with low Bath AS Disease Activity Index (BASDAI) during biologic therapy. Design Using data from multi-center, prospective, observational prospective cohort, Korean College
-
Impact of csDMARDs adherence on clinical remission in patients with new-onset inflammatory arthritis: a prospective cohort study from the ELECTRA database. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-10-04 Anna Zanetti,Antonella Zambon,Carlo A Scirè,Serena Bugatti,Carlomaurizio Montecucco,Garifallia Sakellariou
Background Major improvements in the management of rheumatoid arthritis (RA) have made clinical remission an achievable and desirable goal but, despite the relevance gained by a profound disease suppression, many patients with RA still miss clinical remission due to several factors influencing disease activity, including treatment adherence. Objective To evaluate the effect of adherence to conventional
-
Factors associated with radiographic progression in rheumatoid arthritis starting biological diseases modifying anti-rheumatic drugs (bDMARDs). Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-09-28 Giovanni Adami,Angelo Fassio,Francesca Pistillo,Camilla Benini,Ombretta Viapiana,Maurizio Rossini,Davide Gatti
Background Biological DMARDs (bDMARDs) have been proven to prevent joint damage and bone erosions. Nevertheless, approximately 15% of rheumatoid arthritis (RA) patients on bDMARDs will progress despite good control of joint inflammation. Objectives The objective of our study is to investigate the factors associated with radiological progression of patients treated with bDMARDs. Design We conducted
-
The burden of low back pain in children and adolescents with overweight and obesity: from pathophysiology to prevention and treatment strategies. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-09-08 Luca Ambrosio,Giorgia Mazzuca,Alice Maguolo,Fabrizio Russo,Francesca Cannata,Gianluca Vadalà,Claudio Maffeis,Rocco Papalia,Vincenzo Denaro
Nonspecific low back pain (LBP) is one of the most common causes of disability, affecting all individuals at least once in their lifetime. Such a condition is also becoming increasingly frequent in the pediatric population, especially in children and adolescents with overweight/obesity. Furthermore, new-onset LBP during adolescence has been demonstrated to be a strong predictor of developing LBP later
-
Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases: a study of treatment trajectories on a patient level in routine care. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-09-08 Imke Redeker,Stefan Moustakis,Styliani Tsiami,Xenofon Baraliakos,Ioana Andreica,Bjoern Buehring,Jürgen Braun,Uta Kiltz
Background Previous experiences with non-medical switching of adalimumab (ADA) in patients with chronic inflammatory rheumatic diseases (CIRD) come mainly from phase III extension of randomised clinical trials and little from routine care. Objectives To analyse treatment trajectories over 2 years in patients with CIRD conducting a non-medical switch from originator to biosimilar ADA. Design A retrospective
-
Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-09-08 Oliver FitzGerald,Frank Behrens,Anne Barton,Heidi Bertheussen,Bruno Boutouyrie-Dumont,Laura Coates,Owen Davies,Maarten de Wit,Filippo Fagni,Carl S Goodyear,Robert Gurke,Lisa Hahnefeld,Christine Huppertz,Vassilios Ioannidis,Mark Ibberson,Arnon Katz,Maximilian Klippstein,Michaela Koehm,Shimon Korish,Sina Mackay,David A Martin,Denis O'Sullivan,Khadijah Patel,Stefan Rueping,Georg Schett,Klaus Scholich
Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative
-
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-09-08 Giovanni Iolascon,Sara Liguori,Marco Paoletta,Giuseppe Toro,Antimo Moretti
Bone fragility is the determinant of the increased risk of minimal trauma fracture and must be treated with a multimodal approach that includes pharmacological therapy, physical exercise, and adequate nutrition. Pharmacological therapy, to date based on the administration of antiresorptive drugs, such as bisphosphonates and denosumab, or osteoanabolic drugs, such as teriparatide and abaloparatide,
-
Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-08-30 Martin Rudwaleit,Pedro M Machado,Vanessa Taieb,Natasha de Peyrecave,Bengt Hoepken,Lianne S Gensler
Background Patients with active axial spondyloarthritis (axSpA) exhibit more absences and lower levels of productivity in the workplace and household than the general population, which can improve upon treatment. Objectives The objective of this study is to determine the long-term impact of achieving different levels of clinical response or disease activity on workplace and household productivity in
-
Dysfunctional high-density lipoprotein in chronic inflammatory rheumatic diseases. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-08-25 Sabina Waldecker-Gall,Felix Seibert,Sebastian Bertram,Adrian Doevelaar,Jürgen Braun,Xenofon Baraliakos,Nina Babel,Christoph Waldecker,Linda Scharow,Nikolaos Pagonas,Timm H Westhoff
Background The mechanism explaining low cholesterol concentrations in chronic inflammatory rheumatic disease (CIRD) is incompletely understood. We hypothesized that chronic inflammation impairs the functionality of high-density lipoprotein (HDL), for example, by oxidative processes. Objectives Assessment of oxidized HDL (HDLox), a marker of dysfunctional HDL, in newly diagnosed patients with CIRD before
-
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-08-24 Atul Deodhar,Dafna Gladman,Rebecca Bolce,David Sandoval,So Young Park,Soyi Liu Leage,Peter Nash,Denis Poddubnyy
Background Psoriatic arthritis (PsA) is a chronic inflammatory condition predominantly affecting the peripheral joints. However, some patients with PsA can experience axial involvement which is manifested with back pain and associated with increased burden of illness. Objectives The aim of this post hoc analysis was to determine the efficacy of ixekizumab (IXE) up to 52 weeks in reducing axial symptoms
-
Drug switching in axial spondyloarthritis patients in Germany - a social listening analysis. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-08-08 Maria Kahn,Steffeni Papukchieva,Axel Fehr,Markus Eberl,Berenice Rösler,Justyna Veit,Benjamin Friedrich,Denis Poddubnyy
Background Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which primarily affects the axial skeleton resulting in chronic back pain and stiffness. According to the guideline, the first-line treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and non-pharmacological treatment. Second line treatment
-
Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-08-01 Yosuke Kunishita,Kento Ichikawa,Yuji Uzawa,Masaki Mitsuhashi,Yuji Yoshioka,Tadanobu Okubo,Shouhei Nagaoka
Background Abatacept (ABT) is known to lower infection risk than other biologics and is effective and safe in elderly patients with rheumatoid arthritis (RA). However, there were inconsistent reports on the impact of ABT on malignancies which are more common in the elderly and strongly related to prognosis. Objectives This study aimed to evaluate the efficacy and safety of ABT in patients with RA with
-
A prognostic immune nutritional index can predict all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-07-29 Sung Soo Ahn,Jung Yoon Pyo,Jason Jungsik Song,Yong-Beom Park,Sang-Won Lee
Background Studies have proposed that nutritional and immune-related markers are relevant with patient outcomes of various medical conditions and could be a useful indicator of patient prognostication. Objectives This study investigated whether a prognostic immune nutritional index (PINI) at diagnosis could predict adverse clinical outcomes in patients with antineutrophil cytoplasmic antibody-associated
-
Oral enzyme combination with bromelain, trypsin and the flavonoid rutoside reduces systemic inflammation and pain when used pre- and post-operatively in elective total hip replacement: a randomized exploratory placebo-controlled trial. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-07-29 Jiří Vosáhlo,Adam Salus,Michael Smolko,Barbora Němcová,Veit Nordmeyer,Milos Mikles,Stefanie M Rau,Odd Erik Johansen
Background Early mobilization after total hip replacement (THR) is key for fast recovery but is often limited by pain. Oral enzyme combinations (OECs) have demonstrated anti-inflammatory and pain-relieving effects. Objectives and design This prospective, randomized, double-blind, placebo-controlled exploratory trial evaluated the effects of pre- and post-operative use of OEC (90 mg bromelain, 48 mg
-
New insights in lower limb reconstruction strategies. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-07-29 Giuseppe Toro,Antonio Benedetto Cecere,Adriano Braile,Annalisa De Cicco,Sara Liguori,Umberto Tarantino,Giovanni Iolascon
High Energy Musculoskeletal Traumas (HEMTs) represent a relevant problem for healthcare systems, considering the high social costs, and both the high morbidity and mortality. The poor outcomes associated with HEMT are related to the high incidence of complications, including bone infection, fracture malunion and non-union. The treatment of each of these complications could be extremely difficult. Limb
-
Utilising a non-surgical intervention in the knee osteoarthritis care pathway: a 6-year retrospective audit on NHS patients. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-07-29 Robyn Benn,Lewis Rawson,Amanda Phillips
Background Knee osteoarthritis (OA) is a chronic, debilitating, musculoskeletal condition that affects millions. The increase in prevalence and its economic impact on healthcare and society raise the need for additional non-surgical interventions. Objective To assess the referral rates to secondary care consultation and clinical outcomes in patients with severe knee OA treated with a home-based, non-surgical
-
Myths and truths on biophysics-based approach in rehabilitation of musculoskeletal disorders. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-07-19 Alessandro de Sire,Lorenzo Lippi,Nicola Marotta,Martina Ferrillo,Arianna Folli,Alessio Turco,Antonio Ammendolia,Marco Invernizzi
Musculoskeletal disorders (MSD) are a crucial issue in current literature due to their impact on physical function, social, and economic costs. Rehabilitation plays a pivotal role in the therapeutic management of these disabling conditions with growing evidence underlining positive effects in improving functional outcomes. However, to date, several questions are still open about the mechanisms underpinning
-
Mechanisms hypothesized for pain-relieving effects of exercise in fibromyalgia: a scoping review. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-07-16 Yuva Venkata Raghava Neelapala,Domenico Mercuri,Luciana Macedo,Steven Hanna,Dylan Kobsar,Lisa Carlesso
Background Exercise is one of the most recommended management strategies by treatment guidelines for fibromyalgia (FM); however, the mechanism through which exercise improves pain in FM is still unknown. Objective We aimed to summarize the hypothesized theoretical mechanisms for the pain-relieving effects of exercise in people with FM. Eligibility Criteria Randomized controlled trials (RCTs) in English
-
Clinical characteristics of myositis patients with isolated anti-U1 ribonucleoprotein antibody resemble immune-mediated necrotizing myopathy. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-07-14 Yongpeng Ge,Hongxia Yang,Wei Jiang,Xiaolan Tian,Xin Lu,Guochun Wang
Background Anti-U1 ribonucleoprotein (U1RNP) antibodies were associated with connective tissue diseases (CTDs), but the clinical characteristics of this antibody in Chinese myositis patients have not been studied. Objective We aim to analyze the clinical features of myositis patients who test positive for anti-U1RNP antibodies and delineate a subgroup of myositis. Design This is a retrospective cohort
-
Comparative validation of the knee inflammation MRI scoring system and the MRI osteoarthritis knee score for semi-quantitative assessment of bone marrow lesions and synovitis-effusion in osteoarthritis: an international multi-reader exercise. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-07-12 Walter P Maksymowych,Jacob L Jaremko,Susanne J Pedersen,Iris Eshed,Ulrich Weber,Andrew McReynolds,Paul Bird,Stephanie Wichuk,Robert G Lambert
Background Bone marrow lesions (BMLs) and synovitis on magnetic resonance imaging (MRI) are associated with symptoms and predict degeneration of articular cartilage in osteoarthritis (OA). Validated methods for their semiquantitative assessment on MRI are available, but they all have similar scoring designs and questionable sensitivity to change. New scoring methods with completely different designs
-
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-07-04 Dylan McGagh,Niall McGowan,Chris Hinds,Kate E A Saunders,Laura C Coates
Background Psoriatic arthritis (PsA) is associated with sleep disturbance, depression and a lifetime risk of obesity and cardiovascular disease. To date, there have been no studies investigating the relationship between objectively-measured physical activity (PA) levels and circadian rhythm disturbance with disease activity, daily symptoms and mood in patients with PsA. Objective This pilot study aimed
-
Emerging molecular biomarkers in osteoarthritis pathology. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-06-19 Amit Sandhu,Jason S Rockel,Starlee Lively,Mohit Kapoor
Osteoarthritis (OA) is the most common form of arthritis resulting in joint discomfort and disability, culminating in decline in life quality. Attention has been drawn in recent years to disease-associated molecular biomarkers found in readily accessible biofluids due to low invasiveness of acquisition and their potential to detect early pathological molecular changes not observed with traditional
-
Medication holidays in osteoporosis: evidence-based recommendations from the Italian guidelines on 'Diagnosis, risk stratification, and continuity of care of fragility fractures' based on a systematic literature review. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-06-19 Silvia Migliaccio,Antimo Moretti,Annalisa Biffi,Raffaella Ronco,Gloria Porcu,Giovanni Adami,Rosaria Alvaro,Riccardo Bogini,Achille Patrizio Caputi,Luisella Cianferotti,Bruno Frediani,Davide Gatti,Stefano Gonnelli,Andrea Lenzi,Salvatore Leone,Tiziana Nicoletti,Marco Paoletta,Annalisa Pennini,Eleonora Piccirilli,Raffaella Michieli,Umberto Tarantino,Maurizio Rossini,Giovanni Corrao,Maria Luisa Brandi
Background Noncommunicable, chronic diseases need pharmacological interventions for long periods or even throughout life. The temporary or permanent cessation of medication for a specific period, known as a 'medication holiday,' should be planned by healthcare professionals. Objectives We evaluated the association between continuity (adherence or persistence) of treatment and several outcomes in patients
-
T-score discordance between hip and lumbar spine: risk factors and clinical implications. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-06-19 Ming-Hsiu Chiang,Yeu-Chai Jang,Yu-Pin Chen,Wing P Chan,Ying-Chin Lin,Shu-Wei Huang,Yi-Jie Kuo
Background T-score discordance is common in osteoporosis diagnosis and leads to problems for clinicians formulating treatment plans. Objectives This study investigated the potential predictors of T-score discordance and compared fracture risk among individuals with varying T-score discordance status. Design This was a single-center cross-sectional study conducted at Wan Fang Hospital, Taipei City,
-
Role of imaging for eligibility and safety of a-NGF clinical trials. Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-05-29 Frank W Roemer,Marc C Hochberg,John A Carrino,Andrew J Kompel,Luis Diaz,Daichi Hayashi,Michel D Crema,Ali Guermazi
Nerve growth factor (a-NGF) inhibitors have been developed for pain treatment including symptomatic osteoarthritis (OA) and have proven analgesic efficacy and improvement in functional outcomes in patients with OA. However, despite initial promising data, a-NGF clinical trials focusing on OA treatment had been suspended in 2010. Reasons were based on concerns regarding accelerated OA progression but
-
Latest insights in disease-modifying osteoarthritis drugs development Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-05-13 Shengfa Li, Peihua Cao, Tianyu Chen, Changhai Ding
Osteoarthritis (OA) is a prevalent and severely debilitating disease with an unmet medical need. In order to alleviate OA symptoms or prevent structural progression of OA, new drugs, particularly d...
-
Systemic sclerosis associated interstitial lung disease: a survey of current practices in France Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-05-09 Amélie Nicolas, Sylvie Leroy, Luc Mouthon, Yurdagul Uzunhan, Vincent Cottin, Arsene Mekinian, Viviane Queyrel, Eric Hachulla, Benoit Gachet, David Launay, Nihal Martis, Groupe Orphalung, Groupe Francophone de Recherche sur la Sclérodermie
Background:Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis (SSc).Objective:We performed an overview of the diagnostic approaches, follow-up and treatment str...
-
Magnetic resonance imaging assessments for knee segmentation and their use in combination with machine/deep learning as predictors of early osteoarthritis diagnosis and prognosis Thera. Adv. Musculoskelet. Dis. (IF 3.4) Pub Date : 2023-04-28 Johanne Martel-Pelletier, Patrice Paiement, Jean-Pierre Pelletier
Knee osteoarthritis (OA) is a prevalent and disabling disease that can develop over decades. This disease is heterogeneous and involves structural changes in the whole joint, encompassing multiple ...